US 11,654,143 B2
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
Ahmed Hamdy, Santa Cruz, CA (US); Wayne Rothbaum, Delray Beach, FL (US); Raquel Izumi, San Carlos, CA (US); Brian Lannutti, Solana Beach, CA (US); Todd Covey, San Carlos, CA (US); Roger Ulrich, Sammamish, WA (US); David M. Johnson, Aptos, CA (US); Tjeerd Barf, Ravenstein (NL); and Allard Kaptein, Zaltbommel (NL)
Assigned to Acerta Pharma B.V., Oss (NL)
Filed by Acerta Pharma B.V., Oss (NL)
Filed on Jul. 8, 2021, as Appl. No. 17/370,827.
Application 17/370,827 is a continuation of application No. 15/982,525, filed on May 17, 2018, granted, now 11,166,951.
Application 15/982,525 is a continuation of application No. 15/503,217, abandoned, previously published as PCT/IB2015/056126, filed on Aug. 11, 2015.
Claims priority of provisional application 62/181,160, filed on Jun. 17, 2015.
Claims priority of provisional application 62/115,497, filed on Feb. 12, 2015.
Claims priority of provisional application 62/088,240, filed on Dec. 5, 2014.
Claims priority of provisional application 62/035,795, filed on Aug. 11, 2014.
Prior Publication US 2022/0088013 A1, Mar. 24, 2022
Int. Cl. A61K 31/4985 (2006.01); A61K 31/519 (2006.01); A61K 31/4468 (2006.01); A61K 45/06 (2006.01); A61K 31/675 (2006.01); A61K 31/437 (2006.01); A61P 35/00 (2006.01); A61K 31/454 (2006.01); A61K 31/52 (2006.01); A61K 31/635 (2006.01)
CPC A61K 31/4985 (2013.01) [A61K 31/437 (2013.01); A61K 31/4468 (2013.01); A61K 31/454 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61K 31/635 (2013.01); A61K 31/675 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 21 Claims
 
1. A method of treating chronic lymphocytic leukemia, comprising administering, to a human subject in need thereof, therapeutically effective amounts of (1) a B-cell lymphoma 2 (BCL-2) inhibitor of the formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, (2) a Bruton's tyrosine kinase (BTK) inhibitor of the formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and (3) obinutuzumab.